foritinib (SAF-189) / Fosun Pharma 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
foritinib (SAF-189) / Fosun Pharma
SAF-189-III101, CTR20213144: A multicenter, open-label, randomized controlled phase III clinical study comparing the efficacy and safety of succinate versicitinib versus crizotinib in treatment-naïve ALK-positive patients with advanced or metastatic non-small cell lung cancer (NSCLC)

Active, not recruiting
3
275
China
foritinib (SAF-189) - Fosun Pharma, Xalkori (crizotinib) - Pfizer
Shanghai Institute of Materia Medical;Chinese Academy of Sciences/ Chongqing Fuchuang Pharmaceutical Research Co., Ltd
Anaplastic lymphoma kinase-positive (ALK-positive) non-small cell lung cancer (NSCLC)
 
 
SAF-189-III101, NCT06569420: Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC

Active, not recruiting
3
275
RoW
Drug: Foritinib Succinate, SAF-189s, Drug: Crizotinib
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Non-Small Cell Lung Cancer, ALK-positive, SAF-189s
07/25
12/27
NCT04237805 / 2013-001045-14: A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients

Recruiting
1/2
280
RoW
SAF-189s, foritinib succinate
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Advanced Cancer, Advanced Solid Tumor, Lung Cancer, Nonsmall Cell
12/22
03/26
ChiCTR2200067008: A Food-Effect Study of Foritinib Succinate in Healthy Participants

Completed
1
24
 
fast+fed ;fed+fast
The Second Hospital of Anhui Medical University; The Second Hospital of Anhui Medical University, Wanbang Biopharmaceuticals
cancer
 
 
NCT06717880: A Study of IBI363 in Combination With Bevacizumab or Furuitinib in Subjects With Advanced Colorectal Cancer

Recruiting
1
260
RoW
IBI363 combined with Bevacizumab, IBI363 + Furuitinib
Wuhan Union Hospital, China
Advanced Malignancies
07/25
07/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
foritinib (SAF-189) / Fosun Pharma
SAF-189-III101, CTR20213144: A multicenter, open-label, randomized controlled phase III clinical study comparing the efficacy and safety of succinate versicitinib versus crizotinib in treatment-naïve ALK-positive patients with advanced or metastatic non-small cell lung cancer (NSCLC)

Active, not recruiting
3
275
China
foritinib (SAF-189) - Fosun Pharma, Xalkori (crizotinib) - Pfizer
Shanghai Institute of Materia Medical;Chinese Academy of Sciences/ Chongqing Fuchuang Pharmaceutical Research Co., Ltd
Anaplastic lymphoma kinase-positive (ALK-positive) non-small cell lung cancer (NSCLC)
 
 
SAF-189-III101, NCT06569420: Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC

Active, not recruiting
3
275
RoW
Drug: Foritinib Succinate, SAF-189s, Drug: Crizotinib
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Non-Small Cell Lung Cancer, ALK-positive, SAF-189s
07/25
12/27
NCT04237805 / 2013-001045-14: A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients

Recruiting
1/2
280
RoW
SAF-189s, foritinib succinate
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Advanced Cancer, Advanced Solid Tumor, Lung Cancer, Nonsmall Cell
12/22
03/26
ChiCTR2200067008: A Food-Effect Study of Foritinib Succinate in Healthy Participants

Completed
1
24
 
fast+fed ;fed+fast
The Second Hospital of Anhui Medical University; The Second Hospital of Anhui Medical University, Wanbang Biopharmaceuticals
cancer
 
 
NCT06717880: A Study of IBI363 in Combination With Bevacizumab or Furuitinib in Subjects With Advanced Colorectal Cancer

Recruiting
1
260
RoW
IBI363 combined with Bevacizumab, IBI363 + Furuitinib
Wuhan Union Hospital, China
Advanced Malignancies
07/25
07/26

Download Options